Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1757-2215
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer ; volume:12 ; number:1 ; day:29 ; month:12 ; year:2019 ; pages:1-10 ; date:12.2019
Journal of ovarian research ; 12, Heft 1 (29.12.2019), 1-10, 12.2019
- Creator
-
Wu, Huan
Li, Rongrong
Zhang, Zhiwei
Jiang, Huiyang
Ma, Hanlin
Yuan, Cunzhong
Sun, Chenggong
Li, Yingwei
Kong, Beihua
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13048-019-0601-6
- URN
-
urn:nbn:de:101:1-2020053022473225912918
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wu, Huan
- Li, Rongrong
- Zhang, Zhiwei
- Jiang, Huiyang
- Ma, Hanlin
- Yuan, Cunzhong
- Sun, Chenggong
- Li, Yingwei
- Kong, Beihua
- SpringerLink (Online service)
Other Objects (12)
Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients
Histopathologic image–based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer
Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer
Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma
High-grade serous ovarian cancer: the clone wars
High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis
Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
Benign serous ovarian tumour: a redefining moment?
Network vulnerability-based and knowledge-guided identification of microRNA biomarkers indicating platinum resistance in high-grade serous ovarian cancer
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial
Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients
Histopathologic image–based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer
Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer
Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma
High-grade serous ovarian cancer: the clone wars
High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis
Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
Benign serous ovarian tumour: a redefining moment?
Network vulnerability-based and knowledge-guided identification of microRNA biomarkers indicating platinum resistance in high-grade serous ovarian cancer
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial
Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients
Histopathologic image–based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer
Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer
Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma
High-grade serous ovarian cancer: the clone wars
High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis
Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
Benign serous ovarian tumour: a redefining moment?
Network vulnerability-based and knowledge-guided identification of microRNA biomarkers indicating platinum resistance in high-grade serous ovarian cancer